Investment Rating - The report maintains a "Buy" rating for the company [10] Core Insights - The company reported a revenue of 13.96 billion HKD for the first half of 2025, representing a year-on-year increase of 4.4%, primarily driven by growth in the animal nutrition segment [2][6] - The net profit attributable to shareholders reached 1.79 billion HKD, a significant year-on-year increase of 72.1%, mainly due to higher gross margins in the food additives and animal nutrition divisions [2][6] - The interim dividend declared is 0.365 HKD per share, which includes basic interim dividends, special interim dividends, and tax-exempt compensation [2][6] Summary by Sections Revenue and Profitability - The company achieved a revenue of 13.96 billion HKD, with the animal nutrition segment being the key contributor [2][6] - The net profit attributable to shareholders was 1.79 billion HKD, reflecting a substantial increase due to improved gross margins [2][6] Segment Performance - The food additives segment generated revenue of 6.47 billion HKD, with a gross margin of 15.8% [8] - The animal nutrition segment reported revenue of 5.41 billion HKD, with a gross margin of 28.2% [8] - The high-end amino acids segment achieved a revenue of 1.05 billion HKD, with a gross margin of 40.7% [8] Market Dynamics - The company is a leading player in the global monosodium glutamate industry, with expectations of increased demand as the industry recovers [8] - The company is actively expanding its international presence, with new production capacities coming online and a project in Kazakhstan underway [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The clinical data indicates an ultra-long half-life for ASC30, which is expected to be launched as a quarterly formulation [7] - ASC30 has shown a 75-day apparent half-life in obese subjects, suggesting the potential for a long-term weight management solution with quarterly dosing [7] - The safety data for ASC30 is excellent, with no serious adverse events reported, supporting the possibility of higher dosing [7] - The Ultra-Long-Acting Platform (ULAP) will facilitate the development of various subcutaneous injection formulations [7] - The company has multiple catalysts in the second half of the year, with important clinical data expected to be disclosed [7] - Revenue forecasts for 2025 are set at 0.02 billion, 0.64 billion, and 2.03 billion for 2025, 2026, and 2027 respectively, with a maintained "Buy" rating [7] Financial Summary - Total revenue for 2023 is projected at 56.69 million, with a significant increase expected in 2026 at 64.43 million and 203.23 million in 2027 [1][8] - The net profit attributable to the parent company is forecasted to be negative, with figures of (144.72) million in 2023 and (358.40) million in 2027 [1][8] - The earnings per share (EPS) is expected to improve from (0.15) in 2023 to (0.37) in 2027 [1][8] - The price-to-earnings (P/E) ratio is projected to decrease from (54.06) in 2023 to (21.83) in 2027 [1][8]

Investment Rating - The report maintains an "Outperform" rating with a target price of 15.52 HKD per share [4][13]. Core Insights - The company has shown strong performance in its payment business, with a total payment volume (TPV) growth of 94% year-on-year in global payments and a significant increase in net profit due to substantial investment gains [4][15]. - The company is strategically investing in the Web3.0 ecosystem, allocating 50% of the funds raised from a recent share placement to blockchain innovations in global payments [4][16]. Financial Summary - Revenue for H1 2025 reached 783 million RMB, up 26.8% year-on-year, while net profit turned positive at 1.51 billion RMB, primarily due to the sale of a subsidiary stake [4][14]. - The gross margin stood at 51.9%, with a slight decrease of 0.7 percentage points year-on-year, and overall expense ratios showed significant optimization [4][14]. - The company forecasts revenue growth for 2025-2027, with total revenues projected at 1,652 million RMB in 2025, 2,089 million RMB in 2026, and 2,577 million RMB in 2027, reflecting growth rates of 25.7%, 26.4%, and 23.4% respectively [3][4]. Business Performance - The digital payment segment generated 684 million RMB in revenue for H1 2025, marking a 26.2% increase year-on-year, with total TPV reaching 2.1 trillion RMB, up 32.0% year-on-year [4][15]. - The company has a robust customer base of 7.9 million, supported by 65 global payment licenses, indicating strong future growth potential in transaction volumes [4][15]. Web3.0 Ecosystem Investment - The company completed a share placement in July 2025, raising 387 million HKD, with plans to invest in blockchain technology for global payments [4][16]. - The acquisition of a Hong Kong VATP license positions the company to enhance its digital asset capabilities and ecosystem [4][16].

丨证券研究报告丨 彭英骐 刘长洪 SAC：S0490524030005 SAC：S0490525070007 SFC：BUZ392 请阅读最后评级说明和重要声明 %% %% %% %% 港股研究丨公司点评丨三生制药（1530.HK） [Table_Title] 收获期迸发对外合作，长期增长显著 报告要点 [Table_Summary] 2025 年 H1 三生制药实现归母净利润 13.58 亿元，同比增长 24.6%；营业收入 43.55 亿元；研 发支出 5.48 亿元，同比增长 15%；经调整的非经营性 EBITDA 16.10 亿元。与辉瑞就 PD- 1/VEGF 双抗 SSGJ-707 达成 15 亿美元前端交易付款的重磅交易，且四大治疗领域 13 条管线 接近收获期，迸发增长动力。 分析师及联系人 [Table_Author] research.95579.com 1 三生制药（1530.HK） cjzqdt11111 [Table_Title2] 收获期迸发对外合作，长期增长显著 [Table_Summary2] 事件描述 2025 年 8 月 29 日，三生制药发布 2025 年中期业绩公告：2 ...

业绩拐点确立，"一模一体两翼"战略加速落地 2025 年中报点评 本报告导读： 业绩拐点确立，盈利能力大幅改善。 "AI+制造"战略成果显著，成为增长核心引擎。 "一模一体两翼"战略加速落地。 投资要点： 请务必阅读正文之后的免责条款部分 海 外 公 司 ( 中 财务摘要(百万人民币) 2023A 2024A 2025E 2026E 2027E 营业总收入 1752.55 1221.77 1500.95 1854.82 2276.28 (+/-)% 12.5% -30.3% 22.9% 23.6% 22.7% 毛利润 588.49 423.07 535.68 675.66 846.21 净利润 -582.34 -593.81 -154.33 -115.88 -47.69 (+/-)% -60.4% -2.0% 74.0% 24.9% 58.8% PE -8.83 -5.34 -30.16 -40.14 -98.49 PB 2.58 2.13 3.34 3.64 3.78 资料来源：Wind，HTI 研究 国 香 港 ) 证 券 研 究 报 告 股 票 研 究 股票研究 /[Table_Date] 2025.0 ...

Investment Rating - Maintain "Outperform" rating, with a target price of 4.23 HKD/share, reflecting a 29% reduction from previous estimates [8][9]. Core Insights - The company has ample orders and growth momentum across major sectors, with new orders doubling year-on-year [9][10]. - The "Data x AI" strategy is being continuously advanced, enhancing the company's capabilities in delivering intelligent solutions across various scenarios [11]. Financial Summary - For 2025H1, the company achieved revenue of 7.87 billion RMB, a year-on-year increase of 12.04%, and a net profit attributable to shareholders of 15 million RMB, up 40.70% year-on-year [9][10]. - New orders in 2025H1 were approximately 9.48 billion RMB, representing a 98% year-on-year growth, with total orders on hand reaching 10.44 billion RMB, up 27% year-on-year [9][10]. - The three main business sectors showed growth: big data products and solutions revenue increased by 12% to 1.43 billion RMB, software and operation services revenue rose by 13% to 2.45 billion RMB, and information innovation and traditional services revenue grew by 11% to 3.99 billion RMB [10][11]. Business Strategy - The company is focusing on the "Data x AI" strategy, which includes the development of the "YanCloud Infinity Platform" to enhance data intelligence capabilities [11]. - Successful implementations of intelligent solutions in smart supply chain and government-enterprise digitalization scenarios have been noted, showcasing the effectiveness of the company's strategic initiatives [11].

Investment Rating - The report maintains a "Buy" rating for Kuaishou Technology (01024) [6] Core Insights - Kuaishou's Q2 2025 revenue reached 35.046 billion CNY, a year-on-year increase of 13.1%, with adjusted net profit of 5.618 billion CNY, up 20.1%, achieving a record quarterly adjusted net profit margin of 16.0%, exceeding market expectations [6] - The company declared its first special dividend since listing, distributing 0.46 HKD per share, totaling approximately 2 billion HKD [6] - Kuaishou's daily active users (DAU) reached 409 million, a 3.4% year-on-year increase, while monthly active users (MAU) reached 715 million, up 3.3%, with user engagement at 57.2% [6] - The OneRec end-to-end recommendation system contributed to stable traffic growth, with average daily usage time of 126.8 minutes, a 7.5% year-on-year increase [6] Financial Data and Earnings Forecast - Revenue projections for Kuaishou are as follows: - 2023: 113.47 billion CNY - 2024: 126.90 billion CNY - 2025E: 142.71 billion CNY - 2026E: 156.47 billion CNY - 2027E: 171.03 billion CNY - Adjusted net profit forecasts are: - 2023: 10.27 billion CNY - 2024: 17.72 billion CNY - 2025E: 20.25 billion CNY - 2026E: 22.93 billion CNY - 2027E: 26.67 billion CNY - The report adjusts revenue forecasts downwards for 2025-2027 due to short-term macro pressures, with new estimates of 142.71 billion CNY, 156.47 billion CNY, and 171.03 billion CNY respectively [3][7] Business Performance - Kuaishou's online marketing revenue for Q2 2025 was 19.8 billion CNY, a 12.8% year-on-year increase, with e-commerce GMV reaching 358.9 billion CNY, up 17.6% [6] - The company’s other revenue sources grew by 26% year-on-year, exceeding market expectations [6] - The introduction of the Keling AI technology has led to significant improvements in model quality and performance, contributing to revenue of 250 million CNY in Q2 2025, surpassing expectations [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company reported stable operations in the first half of the year with a significant decrease in capital expenditures [5] - The company achieved a revenue of 6.845 billion RMB in the first half, a year-on-year increase of 3.26%, while net profit decreased by 4.37% [7] - The company plans to distribute a dividend of 0.03 RMB per share, unchanged from the previous year [7] - The increase in power generation was primarily due to new installations, with total power generation reaching 18.9 billion kWh, up 10.22% year-on-year [7] - The company’s controllable installed capacity reached 19.07 million kW, an increase of 22.59% year-on-year [7] - The company’s financial structure is being optimized with a significant reduction in capital expenditures, down 37.43% year-on-year to 2.6 billion RMB [7] Financial Performance and Forecast - Revenue and profit forecasts for the company from 2023 to 2027 are as follows: - Revenue (million RMB): 12,802 in 2023, 12,576 in 2024, 13,333 in 2025E, 14,173 in 2026E, 14,889 in 2027E [6][8] - Net profit (million RMB): 2,240 in 2023, 1,925 in 2024, 1,774 in 2025E, 1,837 in 2026E, 1,907 in 2027E [6][8] - The company’s price-to-earnings ratio (P/E) is projected to be 9.7 for 2025, 9.4 for 2026, and 9.0 for 2027 [6][8] - The company’s average financing cost decreased to 2.48%, down 36 basis points from the beginning of the year [7]

上 市 公 司 社会服务 2025 年 09 月 09 日 东软睿新集团 (09616) ——开拓医养业务，提升多业务协同效应，未来增长可期 报告原因：强调原有的投资评级 买入（维持） | 市场数据： | 2025 年 09 月 08 日 | | --- | --- | | 收盘价（港币） | 2.75 | | 恒生中国企业指数 | 9121.66 | | 52 周最高/最低（港币） | 3.98/2.23 | | H 股市值（亿港币） | 17.77 | | 流通 H 股（百万股） | 646.22 | | 汇率（人民币/港币） | 1.0978 | 一年内股价与基准指数对比走势： -2% 48% 98% 09/09 10/09 11/09 12/09 01/09 02/09 03/09 04/09 05/09 06/09 07/09 08/09 HSCEI 东软睿新集团 资料来源：Bloomberg 相关研究 证券分析师 黄哲 A0230513030001 huangzhe@swsresearch.com 联系人 黄哲 (8621)23297818× huangzhe@swsresearch.com 财务 ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 14.8, representing a potential upside of 51.6% from the current price of HKD 9.76 [2][6]. Core Insights - The company's cloud service business has shown significant growth, with a revenue increase of 30% year-on-year, and it now accounts for 52% of total revenue. The cloud business is expected to maintain a growth rate of over 20% in the next 3-5 years [6]. - The company has transitioned from a loss to profitability in its cloud services segment, achieving a profit of nearly RMB 200 million in the first half of 2025, with a profit margin of 1.6% [6]. - The company is focusing on expanding its customer base by targeting small and medium-sized enterprises (SMEs) and overseas markets, with a particular emphasis on Southeast Asia [6]. Financial Summary - For the fiscal year ending December 31, 2023, the company reported total revenue of RMB 8.29 billion, a year-on-year increase of 19.1%. The net profit attributable to shareholders was RMB 201.63 million, reflecting a growth of 69.9% [3][8]. - The earnings per share (EPS) for 2025 is projected to be RMB 0.46, with a forecasted net profit of RMB 522.37 million [3][8]. - The company’s financial metrics indicate a projected price-to-earnings (P/E) ratio of 21.4 for 2025, decreasing to 12.9 by 2027, suggesting improving valuation over time [3][8].